MedPacto-Genexine, Agreement to Develop Combination Therapy for Anticancer New Drugs
[Asia Economy Reporter Cho Hyun-ui] MedPacto announced on the 12th that it has signed a research and development agreement to confirm the therapeutic effect of combined administration of the anticancer drug candidate 'Vactosertib' and Genexine's immuno-oncology drug candidate 'Hyleukin-7.'
MedPacto's Vactosertib is a drug candidate that inhibits the signaling of transforming growth factor TGF-β (TGF-beta), which impairs the therapeutic effect of immuno-oncology drugs. It regulates the tumor microenvironment to help anticancer drugs attack cancer cells and plays a role in inhibiting cancer proliferation and metastasis. Clinical trials are underway in combination with immuno-oncology drugs from multinational pharmaceutical companies such as MSD and AstraZeneca.
Genexine's Hyleukin-7 is an immuno-oncology drug developed based on interleukin-7 (IL-7), a substance that promotes the growth and activation of immune cells. It helps the proliferation and activation of T cells, which are immune cells in the body.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Kim Sung-jin, CEO of MedPacto, said, "Vactosertib has proven in ongoing clinical trials that it can be combined with various anticancer drugs," adding, "We will continue to enhance the value of Vactosertib through cooperation with major domestic and international companies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
